Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Initial Experience with Evolut FX: How Does It Measure Up?
Session:
SESSÃO DE POSTERS 05 - TAVI 1
Speaker:
Catarina Gregório
Congress:
CPC 2025
Topic:
H. Interventional Cardiology and Cardiovascular Surgery
Theme:
25. Interventional Cardiology
Subtheme:
25.3 Non-coronary Cardiac Intervention
Session Type:
Cartazes
FP Number:
---
Authors:
Catarina Gregório; Miguel Raposo; Ana Abrantes; Marta Vilela; Diogo Ferreira; João Cravo; Miguel Nobre Menezes; João Silva Marques; Claudia Jorge; Pedro Carrilho Ferreira; Fausto J. Pinto; Pedro Cardoso
Abstract
<p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Introduction</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">: The Evolut FX system represents the latest generation of self-expandable aortic valves (SEV). Evidence on real-world results is still building. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Aim</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">: To describe the initial experience with the latest generation of Evolut self-expandable aortic valves and compare it to the previous generation (Evolut Pro +) regarding intra-hospital outcomes. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Methods</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">: We compared results from the first 50 pts submitted to TAVI with Evolut FX (EFX) devices with the last 50 pts receiving an Evolut Pro + (EPP) valve in a single centre, from 2023 to 2024. Clinical, and echocardiographic data were collected and analyzed. For statistical analysis independent sample T tests, Mann-Whitney and Chi-square tests were applied.</span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Results</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">: From the first 50 consecutive pts treated with EFX, 54% were female with a median age of 83.6 (IQR=8) years. Regarding the last 50 consecutive pts treated with the EPP, 58% were female, with a median age of 80.7 (IQR=11) years. There were no significant differences between groups pertaining baseline demographics, comorbidities, electrocardiographic data (Fig 1). </span></span></span><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">Comparing the EFX to EPP population: echocardiographic evaluation at discharge, maximum (16.6 vs 19mmHg) and mean (8.2 vs 9.2 mmHg) transvalvular gradients and doppler velocity index (0.67 vs 0.65) showed no significative difference. </span></span></span><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">Index admission pacemaker implantation (12 vs 19) showed no statistically significant difference. </span></span></span><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">All-cause death in the first month (2 vs 0), stroke during index admission (2 vs 1) and incidence of arterial vascular complications (3 for both groups) were also not significatively different. </span></span></span></p> <p style="text-align:justify"><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000"><strong>Conclusion</strong></span></span></span><span style="font-size:12pt"><span style="font-family:Calibri,sans-serif"><span style="color:#000000">: Our initial experience with the Evolut FX demonstrates comparable intra-hospital outcomes to its predecessor, the Evolut Pro. There seems to be a signal directing towards a lower rate of permanent pacemaker implantation, albeit not statistically significant in our small population. Larger studies are necessary to confirm these results and evaluate long-term outcomes.</span></span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site